
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New data suggest InterMune Inc.'s intravenous oritavancin is as effective as a regimen of vancomycin plus cephalexin in treating patients with complicated skin and skin-structure infections (CSSSI).






